From: Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study
Patient | G | TNM | Histological type | Last treatment pre-CTC collection | CTC/ml | CTM | Progression post-CTC collection (in months) | Death | Treatment post-CTC collection | Sites pre-CTC collection | Site post-CTC collection |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Male | T4N3M1 | C | untreated | 1.0 | no | 4 months (D) | yes | cisplatin+gemcitabine | pleura, lymph nodes, pericardium, bone | pleura, lymph nodes, pericardium, bone |
2 | Male | T2N3M1 | A | pemetrexed+carboplatin | 3.0 | yes | 5 months | yes | docetaxel | lung, liver, lymph nodes | +lung, +liver, lymph nodes, bone |
3 | Female | T4N0M1 | A | pemetrexed | 12.0 | yes | 3 months | no | erlotinib/docetaxel/vinorelbine/nivolumab | lung, pleura | +lung, bone |
4 | Male | T4N0M1 | A | pemetrexed | 3.0 | no | 8 months | no | docetaxel/gemcitabine/navelbine | bone, lymph nodes, CNS | +bone, lymph nodes, CNS |
5 | Male | T2N0M1 | A | gefitinib | 8.0 | no | 5 months | yes | docetaxel/erlotinib | pleura, CNS | +pleura, +CNS |
6 | Female | T1N2M1 | A | bevacizumab | 2.0 | yes | 4 months | yes | erlotinib/pemetrexed/gemcitabine | lung, lymph nodes, adrenal | +lung, +lymph nodes, adrenal |
7 | Male | T4N3M1 | A | untreated | 1.0 | no | 24 months | no | erlotinib/carboplatin+paclitaxel+bevacizumab/pemetrexed | bone, CNS, lung | +bone, +CNS, lung |
8 | Female | T4N3M1 | A | untreated | 18.75 | no | 9 months | no | carboplatin+paclitaxel+bevacizumab/pemetrexed/crizotinib/ceritinib | lung | +lung, bone, CNS, lymph nodes |
9 | Female | T3N2M1 | A | untreated | 3.5 | no | 3 months | yes | carboplatin+pemetrexed/docetaxel | bone, pleura, lymph nodes | bone, pleura, lymph nodes, lung |
10 | Female | T1N1M1 | A | cisplatin+vinorelbine | 4.06 | no | 10 months | no | erlotinib | lung, CNS | +lung, +CNS |
11 | Male | M1 | A | untreated | 0.37 | no | 3 months (D) | yes | untreated | lung, bone, CNS | NT |
12 | Male | T3N0M1 | C | cisplatin+pemetrexed | 1.87 | no | 2 months | yes | gefitinib | liver, lymph nodes, pancreas | liver, lymph nodes, pancreas |
13 | Female | T4N0M1 | A | untreated | 0 | no | 12 months | yes | carboplatin+pemetrexed/docetaxel/gemcitabine | pleura, lymph nodes | pleura, lymph nodes, bone, CNS |
14 | Male | M1 | A | untreated | 3 | no | 3 months (D) | yes | untreated | lung, bone, lymph nodes, CNS, adrenal | NT |
15 | Male | M1 | A | untreated | 0 | no | 8 months | no | carboplatin+paclitaxel+bevacizumab/pemetrexed/docetaxel/nivolumab/erlotinib/gefitinib/gemcitabine | bone, lymph nodes, CNS, mesentery | +bone, +lymph nodes, CNS, mesentery, liver, lung |